Dabur Pharma Forays Into Pak Aanti-cancer Drug Market (India)
This article was originally published in PharmAsia News
Dabur Pharma has made a foray into the anti-cancer drug market in Pakistan and Turkmenistan. "Increasingly, our focus is to expand not only in the developed markets but also in emerging ones. Recently we have started exporting our anti-cancer drugs to Pakistan," says Dabur Pharma Additional Director and Non-Executive Chairman Mohit Burman. The move follows the Pakistan government allowing imports of anti-cancer drugs from India, and the nation's health ministry has already granted permission to two companies, Atco Pharma and AJ Mirza Pharma to import from Dabur Pharma. Dabur Pharma has also started dispatches to Turkmenistan from its dosage form manufacturing unit at Baddi in Himachal Pradesh. Earlier this year, Dabur Pharma acquired the sales and distribution network of Thai firm Biosciences. Meanwhile, the company's drug Intaxel became the first ever generic oncology drug to cross 100 million Baht sales mark in the country. (Click here for more
You may also be interested in...
The Phase III FIDELIO trial of finerenone has been a success but analysts want to see some actual data before declaring it an unqualified one.
Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.
Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.